WO2003011264A3 - Betacarbolinderivate als gaba a-rezeptor-modulatoren mit nmda-antagonistischer aktivitat zur behandlung von zentralnervensystemerkrankungen - Google Patents

Betacarbolinderivate als gaba a-rezeptor-modulatoren mit nmda-antagonistischer aktivitat zur behandlung von zentralnervensystemerkrankungen Download PDF

Info

Publication number
WO2003011264A3
WO2003011264A3 PCT/EP2002/008166 EP0208166W WO03011264A3 WO 2003011264 A3 WO2003011264 A3 WO 2003011264A3 EP 0208166 W EP0208166 W EP 0208166W WO 03011264 A3 WO03011264 A3 WO 03011264A3
Authority
WO
WIPO (PCT)
Prior art keywords
nmda
modulators
betacarboline
gaba
receptor
Prior art date
Application number
PCT/EP2002/008166
Other languages
English (en)
French (fr)
Other versions
WO2003011264A2 (de
Inventor
Christopher Brueckner
Rainer Dorow
Roland Neuhaus
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Priority to EP02791466A priority Critical patent/EP1411939A2/de
Priority to AU2002333262A priority patent/AU2002333262A1/en
Priority to JP2003516495A priority patent/JP2004537567A/ja
Publication of WO2003011264A2 publication Critical patent/WO2003011264A2/de
Publication of WO2003011264A3 publication Critical patent/WO2003011264A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Es wird die Verwendung von GABAA-Rezeptor-Modulatoren mit NMDA-antagonistischer Aktivität zur Herstellung eines Arzneimittels zur Neuroprotektion und die Kombination von GABAA-Rezeptor-Modulatoren mit NMDA-antagonistischer Wirkung und α-Liponsäure oder Dihydro-α-Liponsäure beschrieben.
PCT/EP2002/008166 2001-07-23 2002-07-22 Betacarbolinderivate als gaba a-rezeptor-modulatoren mit nmda-antagonistischer aktivitat zur behandlung von zentralnervensystemerkrankungen WO2003011264A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02791466A EP1411939A2 (de) 2001-07-23 2002-07-22 Betacarbolinderivate als gaba a-rezeptor-modulatoren mit nmda-antagonistischer aktivitaet zur behandlung von zentralnervensystemerkrankungen
AU2002333262A AU2002333262A1 (en) 2001-07-23 2002-07-22 Betacarboline derivatives as gaba a-receptor-modulators having nmda-antagonistic activity for treating diseases of the central nervous system
JP2003516495A JP2004537567A (ja) 2001-07-23 2002-07-22 Ｎｍｄａ拮抗活性を有するｇａｂａａ−受容体モジュレーター

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10136842.9 2001-07-23
DE10136842A DE10136842A1 (de) 2001-07-23 2001-07-23 GABA¶A¶-Rezeptor-Modulatoren mit NMDA-antagonistischer Aktivität

Publications (2)

Publication Number Publication Date
WO2003011264A2 WO2003011264A2 (de) 2003-02-13
WO2003011264A3 true WO2003011264A3 (de) 2003-12-04

Family

ID=7693425

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/008166 WO2003011264A2 (de) 2001-07-23 2002-07-22 Betacarbolinderivate als gaba a-rezeptor-modulatoren mit nmda-antagonistischer aktivitat zur behandlung von zentralnervensystemerkrankungen

Country Status (5)

Country Link
EP (1) EP1411939A2 (de)
JP (1) JP2004537567A (de)
AU (1) AU2002333262A1 (de)
DE (1) DE10136842A1 (de)
WO (1) WO2003011264A2 (de)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239667A1 (de) * 1986-03-20 1987-10-07 Schering Aktiengesellschaft 5- oder 6-substituierte-beta-carbolin-3-carbonsäureester
WO1999064420A1 (en) * 1998-06-12 1999-12-16 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S β-CARBOLINE COMPOUNDS
WO2000064440A1 (en) * 1999-04-22 2000-11-02 Department Of The Army, U.S. Government Treatment of and/or prophylaxis against brain and spinal cord injury
WO2002078680A1 (de) * 2001-02-13 2002-10-10 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Gaba-rezeptor-modulatoren zur behandlung neurodegenerativer erkrankungen des auges

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0632008B1 (de) * 1993-06-01 1998-02-04 Ono Pharmaceutical Co., Ltd. Pentansäurederivate
EP1282414B1 (de) * 2000-05-05 2005-01-05 University of Virginia Patent Foundation Felabamat-derivate zur behandlung von neuropathischem schmerz

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239667A1 (de) * 1986-03-20 1987-10-07 Schering Aktiengesellschaft 5- oder 6-substituierte-beta-carbolin-3-carbonsäureester
WO1999064420A1 (en) * 1998-06-12 1999-12-16 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S β-CARBOLINE COMPOUNDS
WO2000064440A1 (en) * 1999-04-22 2000-11-02 Department Of The Army, U.S. Government Treatment of and/or prophylaxis against brain and spinal cord injury
WO2002078680A1 (de) * 2001-02-13 2002-10-10 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Gaba-rezeptor-modulatoren zur behandlung neurodegenerativer erkrankungen des auges

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GARCIA J J ET AL: "Protective effect of beta-carbolines and other antioxidants on lipid peroxidation due to hydrogen peroxide in rat brain homogenates.", NEUROSCIENCE LETTERS, vol. 294, no. 1, 10 November 2000 (2000-11-10), pages 1 - 4, XP002231148, ISSN: 0304-3940 *
See also references of EP1411939A2 *

Also Published As

Publication number Publication date
AU2002333262A1 (en) 2003-02-17
WO2003011264A2 (de) 2003-02-13
JP2004537567A (ja) 2004-12-16
DE10136842A1 (de) 2003-02-13
EP1411939A2 (de) 2004-04-28

Similar Documents

Publication Publication Date Title
IL153442A0 (en) Treatment of central nervous system diseases by antibodies against glatiramer acetate
WO2004041258A8 (fr) Utilisation d’inhibiteurs des phosphodiesterases des nucleotides cycliques, ayant une structure benzodiazepinique en therapie
WO2002100347A3 (en) Prodrugs of gaba analogs, compositions and uses thereof
WO2003092580A3 (en) Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
WO2007016155A3 (en) Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
WO2003000699A8 (de) Substituierte 1-oxa-2,8-diaza-spiro[4,5]dec-2-en-derivate als arzneimittel gegen schmerz
HU0003863D0 (en) Alpha-sulfonylamino hidroxamic acid inhibitors of matrix metalloproteinases for the treatment of peripheral or central nervous system disorders
AU4331400A (en) Neurotrophic substituted pyrimidines
WO2001098279A3 (en) Bis-arylsulfones
WO2008153937A3 (en) Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
WO2002085853A3 (en) Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
WO2008057575A3 (en) Novel arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
WO2004011464A3 (fr) Nouvelles pyrazolo[1,5-a]-1,3,5-triazines substituees et leurs analogiques, compositions pharmaceutiques les contenant, utilisation a titre de medicament et procedes pour leur preparation
WO2003037863A3 (de) Substituierte indole, verfahren zu deren herstellung und deren verwendung zur schmerzbekämpfung
AU2002227895A1 (en) Sulphonamides for the treatment of central nervous system diseases
WO2002042256A3 (en) N-alkylated gaba compounds, processes for their preparation and their use as medicaments
WO2000040699A3 (en) Astrocytes, their preparation and uses thereof
HK1057332A1 (en) Use of 3-benzoylphenylacetic acid derivatives for the treatment of retinal disorders
WO2003011264A3 (de) Betacarbolinderivate als gaba a-rezeptor-modulatoren mit nmda-antagonistischer aktivitat zur behandlung von zentralnervensystemerkrankungen
WO2007015173A3 (en) Inflammation
AU2003227593A1 (en) New analogs of nitrobenzylthioinosine
AU2003246687A1 (en) Peroxynitrite rearrangement catalysts used for the treatment or prophylaxis of diseases caused by peroxynitrite-mediated reactions
WO2003000269A3 (de) Neue verwendung für pde 10a-inhibitoren
WO2003041657A3 (en) Antisense modulation of vitamin d nuclear receptor expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DK DZ EC EE ES FI GB GD GE GH GM HR ID IL IN IS JP KE KG KP KR KZ LC LK LS LT LU LV MA MD MG MK MN MW MZ NO NZ OM PH PL PT RO RU SD SE SI SK SL TJ TM TN TR TT TZ UA UG VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002791466

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003516495

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002791466

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002791466

Country of ref document: EP